Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients

Thomas Eissenberg; Rolley E. Johnson; George E. Bigelow; Sharon L. Walsh; Ira A. Liebson; Eric C. Strain; Maxine L. Stitzer

doi:10.1016/S0376-8716(97)01347-1

Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients

Thomas Eissenberg, Rolley E. Johnson, George E. Bigelow, Sharon L. Walsh, Ira A. Liebson, Eric C. Strain, Maxine L. Stitzer

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Buprenorphine's clinical utility as an opioid dependence pharmacotherapy may be enhanced with less-than-daily dosing. This study assessed opioid withdrawal after an acute 72 h dose omission in buprenorphine-maintained patients (8 mg/day s.l.). Eight outpatients required to remain free of opioids, cocaine and benzodiazepines completed four double-blind, double-dummy, Latin-square ordered conditions. Test conditions of 8 or 16 mg s.l. buprenorphine were followed by 2 days of placebo dosing. Control conditions were buprenorphine maintenance (8 mg/day), to provide a reference for evaluation of placebo test days and naloxone administration (10 mg/70 kg i.m.) during 8 mg buprenorphine maintenance to assess withdrawal measure sensitivity. Subjective measures and pupil diameter were significantly influenced only by naloxone. The lack of subjective symptoms and physiological signs of opioid withdrawal during 72 h of acute dose omission supports the feasibility of less-than-daily dosing at buprenorphine doses of 8 mg/day in patients who have demonstrated an ability to remain drug-free for an extended period.

Original language	English
Pages (from-to)	81-91
Number of pages	11
Journal	Drug and Alcohol Dependence
Volume	45
Issue number	1-2
DOIs	https://doi.org/10.1016/S0376-8716(97)01347-1
State	Published - Apr 14 1997

Bibliographical note

Funding Information:
The authors thank Robin Clay, Connie Lowery, and Diana Beasley for nursing assistance, Diane Poling for patient counseling, and Richard Hernandez for data management assistance. This research was supported by USPHS grants ROl-DA04011, T32-DA07209, K05-DA00050, and K20-DA0166. Buprenorphine concentrations were determined by the Center for Human Toxicology, University of Utah under NIDA contract no. NOlDA-1-9205.

Keywords

Antagonist-precipitated withdrawal
Buprenorphine
Less-than-daily-dosing
Opioid antagonists
Physical dependence
Spontaneous withdrawal

ASJC Scopus subject areas

Toxicology
Pharmacology
Psychiatry and Mental health
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0376-8716(97)01347-1

Cite this

@article{386c4a1d91d94e3883afcf47de5acdf6,

title = "Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients",

abstract = "Buprenorphine's clinical utility as an opioid dependence pharmacotherapy may be enhanced with less-than-daily dosing. This study assessed opioid withdrawal after an acute 72 h dose omission in buprenorphine-maintained patients (8 mg/day s.l.). Eight outpatients required to remain free of opioids, cocaine and benzodiazepines completed four double-blind, double-dummy, Latin-square ordered conditions. Test conditions of 8 or 16 mg s.l. buprenorphine were followed by 2 days of placebo dosing. Control conditions were buprenorphine maintenance (8 mg/day), to provide a reference for evaluation of placebo test days and naloxone administration (10 mg/70 kg i.m.) during 8 mg buprenorphine maintenance to assess withdrawal measure sensitivity. Subjective measures and pupil diameter were significantly influenced only by naloxone. The lack of subjective symptoms and physiological signs of opioid withdrawal during 72 h of acute dose omission supports the feasibility of less-than-daily dosing at buprenorphine doses of 8 mg/day in patients who have demonstrated an ability to remain drug-free for an extended period.",

keywords = "Antagonist-precipitated withdrawal, Buprenorphine, Less-than-daily-dosing, Opioid antagonists, Physical dependence, Spontaneous withdrawal",

author = "Thomas Eissenberg and Johnson, {Rolley E.} and Bigelow, {George E.} and Walsh, {Sharon L.} and Liebson, {Ira A.} and Strain, {Eric C.} and Stitzer, {Maxine L.}",

note = "Funding Information: The authors thank Robin Clay, Connie Lowery, and Diana Beasley for nursing assistance, Diane Poling for patient counseling, and Richard Hernandez for data management assistance. This research was supported by USPHS grants ROl-DA04011, T32-DA07209, K05-DA00050, and K20-DA0166. Buprenorphine concentrations were determined by the Center for Human Toxicology, University of Utah under NIDA contract no. NOlDA-1-9205.",

year = "1997",

month = apr,

day = "14",

doi = "10.1016/S0376-8716(97)01347-1",

language = "English",

volume = "45",

pages = "81--91",

number = "1-2",

}

TY - JOUR

T1 - Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients

AU - Eissenberg, Thomas

AU - Johnson, Rolley E.

AU - Bigelow, George E.

AU - Walsh, Sharon L.

AU - Liebson, Ira A.

AU - Strain, Eric C.

AU - Stitzer, Maxine L.

N1 - Funding Information: The authors thank Robin Clay, Connie Lowery, and Diana Beasley for nursing assistance, Diane Poling for patient counseling, and Richard Hernandez for data management assistance. This research was supported by USPHS grants ROl-DA04011, T32-DA07209, K05-DA00050, and K20-DA0166. Buprenorphine concentrations were determined by the Center for Human Toxicology, University of Utah under NIDA contract no. NOlDA-1-9205.

PY - 1997/4/14

Y1 - 1997/4/14

N2 - Buprenorphine's clinical utility as an opioid dependence pharmacotherapy may be enhanced with less-than-daily dosing. This study assessed opioid withdrawal after an acute 72 h dose omission in buprenorphine-maintained patients (8 mg/day s.l.). Eight outpatients required to remain free of opioids, cocaine and benzodiazepines completed four double-blind, double-dummy, Latin-square ordered conditions. Test conditions of 8 or 16 mg s.l. buprenorphine were followed by 2 days of placebo dosing. Control conditions were buprenorphine maintenance (8 mg/day), to provide a reference for evaluation of placebo test days and naloxone administration (10 mg/70 kg i.m.) during 8 mg buprenorphine maintenance to assess withdrawal measure sensitivity. Subjective measures and pupil diameter were significantly influenced only by naloxone. The lack of subjective symptoms and physiological signs of opioid withdrawal during 72 h of acute dose omission supports the feasibility of less-than-daily dosing at buprenorphine doses of 8 mg/day in patients who have demonstrated an ability to remain drug-free for an extended period.

AB - Buprenorphine's clinical utility as an opioid dependence pharmacotherapy may be enhanced with less-than-daily dosing. This study assessed opioid withdrawal after an acute 72 h dose omission in buprenorphine-maintained patients (8 mg/day s.l.). Eight outpatients required to remain free of opioids, cocaine and benzodiazepines completed four double-blind, double-dummy, Latin-square ordered conditions. Test conditions of 8 or 16 mg s.l. buprenorphine were followed by 2 days of placebo dosing. Control conditions were buprenorphine maintenance (8 mg/day), to provide a reference for evaluation of placebo test days and naloxone administration (10 mg/70 kg i.m.) during 8 mg buprenorphine maintenance to assess withdrawal measure sensitivity. Subjective measures and pupil diameter were significantly influenced only by naloxone. The lack of subjective symptoms and physiological signs of opioid withdrawal during 72 h of acute dose omission supports the feasibility of less-than-daily dosing at buprenorphine doses of 8 mg/day in patients who have demonstrated an ability to remain drug-free for an extended period.

KW - Antagonist-precipitated withdrawal

KW - Buprenorphine

KW - Less-than-daily-dosing

KW - Opioid antagonists

KW - Physical dependence

KW - Spontaneous withdrawal

UR - http://www.scopus.com/inward/record.url?scp=0031000280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031000280&partnerID=8YFLogxK

U2 - 10.1016/S0376-8716(97)01347-1

DO - 10.1016/S0376-8716(97)01347-1

M3 - Article

C2 - 9179510

AN - SCOPUS:0031000280

SN - 0376-8716

VL - 45

SP - 81

EP - 91

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

IS - 1-2

ER -

Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this